In a noteworthy development for the pharmaceutical industry, Sandoz has received approval from the US Food and Drug Association (FDA) for its biosimilar Tyruko® (natalizumab-sztn). This news, revealed on August 25, 2023, marks the first and only FDA-approved biosimilar authorized specifically for relapsing forms of Multiple Sclerosis (MS).
This injection, developed in close collaboration with Polpharma Biologics, brings hope to a significant number of patients suffering from relapsing forms of MS, a degenerative condition that affects the central nervous system, by providing a new, FDA-approved treatment option.
The significance of this product being a biosimilar, rather than a novel drug, should not be downplayed. Biosimilars are highly similar versions of approved biological products. They hold immense promise for patients because they often cost less than the original drug, making necessary treatments more accessible to the broader population.
For Sandoz, this approval solidifies their commitment to the important field of neuroscience as well as advancing access to biosimilars for patients living with complex diseases. The company continues to burgeon its portfolio in the neuroscience and oncology solutions.
For more details on this development, visit this article on JDSupra.